Ma Yinglongye Subsidiary Receives Drug Approval for Bromfenac Ophthalmic Solution

GateNews
According to an announcement today, Ma Yinglongye's subsidiary Jiangxi Ma Yinglongye Meikang Pharmaceutical obtained a drug registration certificate from China's National Medical Products Administration for bromfenac sodium ophthalmic solution. The medication is indicated for symptomatic treatment of inflammatory diseases of the external eye and anterior eye segment, including conjunctivitis, scleritis, and post-operative inflammation. The approval expands the company's ophthalmology product portfolio.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments